|
|
|
|
|
|
Article Detail
|
|
Label
|
|
|
Label
|
|
|
|
Minocycline as a cardioprotective agent: Mechanistic Insights and Therapeutic Potential
|
|
| Author:
|
, ABHISHEK V. KHADE, SHIBAN J. SAYYED, AARTI M KHANDWAYE, UJWAL N. KATOLKAR, VIVEK S. KUMAWAT, PANKAJ G. JAIN
|
| Abstract:
|
Minocycline (7-Dimethylamino-6-demethyl-6-deoxytetracycline) belongs to the family of semi-synthetic tetracycline, and this drugis traditionally approved as an antibiotic. Based on the preclinical and clinical trials, possessing several therapeutic activities like anti-inflammation, antifibrotic, antioxidants, antiapoptotic, and so on. Minocycline has gained special attention as a promising cardioprotective agent in conditions like chemotherapy-induced cardiotoxicity and ischemia-reperfusion injury. By inhibiting NF-kß and NLRP3 inflammasome activation, it shows anti-inflammatory effects, by enhancing catalase and superoxidase dismutase activity, it shows antioxidant actions, and by preserving mitochondrial function, it shows anti-apoptotic effects. It also diminished the matrix metalloproteinases, reducing fibrosis and balancing extracellular matrix integrity, while regulating calcium homeostasis and autophagy to protect cardiac health. All multifaceted actions make minocycline structural activity relationship strong and special attention to the potential therapeutics option for cardiovascular disorders. However, this drug use requires careful monitoring due to risks such as renal toxicity, nervous system effects, and hypersensitivity reactions. This review highlights and discusses minocycline-mediated cardioprotection, with a special focus on mechanistic pathways involved in chemotherapy-induced cardiotoxicity, ongoing possible biomolecular techniques, and drawbacks are briefly discussed.
|
| Keyword:
|
Minocycline, Cardioprotection, Cardiotoxicity,Anti-inflammatory, Antioxidant, Apoptosis, etc.
|
| EOI:
|
-
|
| DOI:
|
https://doi.org/10.31838/ijpr/2025.17.02.004
|
| Download:
|
Request For Article
|
|
|
|
|
|
|
|
|
|
|